AIM movers: Poor fourth quarter for CMO and Oriole Resources receives earn-in payment

Oriole Resources (LON: ORR) has confirmed receipt of the payment of $450,000 related to the earn-in agreement with BCM International for the Bibemi gold exploration project in Cameroon. BCM will spend $4m on exploration to earn 50% of the project. Drilling should resume in the first quarter. The share price is 17.1% higher at 0.24p.

Data analysis software and services provider Celebrus Technologies (LON: CLBS), formerly D4T4, won four contracts in the fourth quarter. Two new contracts are for three years and are in the retail and healthcare sectors. The other two are extensions of existing contracts with banks. These contracts help to underpin the expected improvement in pre-tax profit from £3.7m to £5.3m in the year to March 2024. The share price increased 9.77% to 236p.

- Advertisement -

Verici Dx (LON: VRCI) says that the Medicare national payment rate for post-kidney transplant test Tutivia and pre-kidney transplant test Clarava are effective from 1 January 2024. The rate for both of them is $2,650. The company’s testing laboratory has been accredited by the College of American Pathology. The share price rose 5.77% to 11p.

Mrs Nashida Islam-Bonnier has cut her stake in podcast platform Audioboom (LON: BOOM) from 3.7% to below 3%. The share price moved up 5.74% to 322.5p.


Online builders’ merchant CMO Group (LON: CMO) had a tough fourth quarter. Online traffic rates declined, but conversion rates improved. Overall orders were flat. Home improvement and DIY spending is declining. The overall repair, maintenance and improvement sector is still relatively strong, but it weakened in the second half of 2023. Market share has grown, and costs have been cut. Liberum has increased its 2023 pre-tax loss forecast from £800,000 to £1.2m and forecasts a 2024 loss. The share price fell 12.7% to 24p.

- Advertisement -

N4 Pharma (LON: N4P) says that its Nuvec silica nanoparticle delivery system for vaccines improved efficacy when mixed with AAV8 vector and used to traduce human-like liver cells. It was 2.5 times better than AAV8 on its own. This means that lower does could be used. Even so, the share price dipped 7.69% to 1.2p although that was from a recent high.

Morocco-based potash project developer Emmerson (LON: EML) is still waiting for government approval of its Environmental and Social Impact Study for the Khemisset potash mine. This requires a ministerial meeting. Debt financing has been extended for 12 months. The share priced declined 6.9% to 1.35p.

On Friday afternoon, Sri Lanka mineral sands project developer Capital Metals (LON: CMET) says that offtake discussions with LB Group are now non-exclusive. There has been additional interest in the Eastern Minerals project. The share price fell on Friday, and it has dropped a further 5.97% to 3.15p.

Consultancy Elixirr International (LON: ELIX) confirmed 2023 results are in line with expectations and it will pay two dividends each year. Pre-tax profit is expected to improve from £19.3m to £23.9m. The shares will go ex-dividend for the 5.3p/share interim on 19 January. Profit-taking knocked 5.65% off the share price leaving it at 585p.  

Latest News

Subscribe to the UK Investor Magazine email newsletter

Register for our free email newsletter and receive the latest investment news, podcasts, event information and offers.

More Articles Like This

Tagdiv Cloud library - template content.